Zimigut 200 Tablet contains Rifaximin 200 mg, a broad-spectrum, non-absorbable antibiotic primarily used to treat gastrointestinal infections caused by susceptible bacteria. Rifaximin acts by inhibiting bacterial RNA synthesis, thereby exerting a bactericidal effect against a wide range of gram-positive and gram-negative aerobic and anaerobic enteric pathogens. Due to its minimal systemic absorption, Zimigut 200 is particularly effective in targeting infections localized within the gastrointestinal tract, including traveler’s diarrhea caused by non-invasive strains of Escherichia coli, hepatic encephalopathy prevention by reducing ammonia-producing gut bacteria, and irritable bowel syndrome with diarrhea (IBS-D). The medication is generally well tolerated, with a low incidence of systemic side effects owing to its localized action. Zimigut 200 should be administered orally as directed by a healthcare professional, with dosage and duration tailored to the specific indication and patient condition. It is contraindicated in patients with known hypersensitivity to rifaximin or any rifamycin derivatives. Caution is advised in patients with severe hepatic impairment. As with all antibiotics, adherence to the prescribed regimen is essential to prevent the development of bacterial resistance. Patients should consult their physician before use, especially if pregnant, breastfeeding, or taking concomitant medications.